1. Home
  2. PRLD vs LOAN Comparison

PRLD vs LOAN Comparison

Compare PRLD & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
    SELLHOLDBUYas of 7 hours ago
  • LOAN
    SELLHOLDBUYas of 7 hours ago
  • Stock Information
  • Founded
  • PRLD 2016
  • LOAN 1989
  • Country
  • PRLD United States
  • LOAN United States
  • Employees
  • PRLD N/A
  • LOAN N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • LOAN Real Estate Investment Trusts
  • Sector
  • PRLD Health Care
  • LOAN Real Estate
  • Exchange
  • PRLD Nasdaq
  • LOAN Nasdaq
  • Market Cap
  • PRLD 73.7M
  • LOAN 57.7M
  • IPO Year
  • PRLD 2020
  • LOAN 1999
  • Fundamental
  • Price
  • PRLD $0.71
  • LOAN $4.85
  • Analyst Decision
  • PRLD Strong Buy
  • LOAN
  • Analyst Count
  • PRLD 2
  • LOAN 0
  • Target Price
  • PRLD $4.50
  • LOAN N/A
  • AVG Volume (30 Days)
  • PRLD 263.3K
  • LOAN 31.0K
  • Earning Date
  • PRLD 05-06-2025
  • LOAN 04-22-2025
  • Dividend Yield
  • PRLD N/A
  • LOAN 9.35%
  • EPS Growth
  • PRLD N/A
  • LOAN 2.37
  • EPS
  • PRLD N/A
  • LOAN 0.49
  • Revenue
  • PRLD $7,000,000.00
  • LOAN $7,351,609.00
  • Revenue This Year
  • PRLD N/A
  • LOAN N/A
  • Revenue Next Year
  • PRLD N/A
  • LOAN $2.18
  • P/E Ratio
  • PRLD N/A
  • LOAN $10.07
  • Revenue Growth
  • PRLD N/A
  • LOAN 1.12
  • 52 Week Low
  • PRLD $0.61
  • LOAN $4.74
  • 52 Week High
  • PRLD $6.80
  • LOAN $6.05
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 48.05
  • LOAN 27.49
  • Support Level
  • PRLD $0.71
  • LOAN $4.74
  • Resistance Level
  • PRLD $0.72
  • LOAN $6.05
  • Average True Range (ATR)
  • PRLD 0.08
  • LOAN 0.21
  • MACD
  • PRLD 0.00
  • LOAN -0.11
  • Stochastic Oscillator
  • PRLD 37.77
  • LOAN 8.40

Stock Price Comparison Chart: PRLD vs LOAN

PRLD
LOAN
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April051015202530354045PRLD VS LOAN

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use